Back to search

Article

MYPP trial: Myo-inositol supplementation to prevent pregnancy complications in women with polycystic ovary syndrome, study protocol for a multicenter, double-blind, randomized controlled trial

2025-04-01

Abstract excerpt

<h4>ABSTRACT</h4> <h4>Introduction</h4> Pregnant women with polycystic ovary syndrome (PCOS) have an increased risk of gestational diabetes mellitus (GDM), preeclampsia and preterm birth, and their offspring are more likely to have an abnormal birth weight and require hospitalization. Current preventive strategies to reduce the rate of pregnancy complications associated with PCOS have ineffective. Myo-inositol sup...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
cbfe630f-6008-571d-991d-6659f3140ed9
DOI
10.1101/2025.04.01.25325030
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
MYPP trial: Myo-inositol supplementation to prevent pregnancy complications in women with polycystic ovary syndrome, study protocol for a multicenter, double-blind, randomized controlled trialDOI 10.1101/2025.04.01.25325030
Myo-inositol versus Metformin in Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis of Anthropometric, Endocrine, Metabolic, and Reproductive OutcomesSemantic proximity
The myo-inositol effect on the oocyte quality and fertilization rate among women with polycystic ovary syndrome undergoing assisted reproductive technology cycles: a randomized clinical trialSemantic proximity
The effect of Myo-Inositol supplement on molecular regulation of folliculogenesis, steroidogenesis, and assisted reproductive technique outcomes in patients with polycystic ovarian syndromeSemantic proximity
Myo-inositol for insulin resistance, metabolic syndrome, polycystic ovary syndrome and gestational diabetesSemantic proximity
The Effects of Myo-Inositol and D-Chiro-Inositol in a Ratio 40:1 on Hormonal and Metabolic Profile in Women with Polycystic Ovary Syndrome Classified as Phenotype A by the Rotterdam Criteria and EMS-Type 1 by the EGOI Criteria.Semantic proximity
Interventions to prevent or delay the onset of type 2 diabetes in women with prior gestational diabetes mellitus: protocol for a living systematic review and prospective meta-analysisSemantic proximity
Effect of a Combination of Myo-Inositol, Alpha-Lipoic Acid, and Folic Acid on Oocyte Morphology and Embryo Morphokinetics in non-PCOS Overweight/Obese Patients Undergoing IVF: A Pilot, Prospective, Randomized StudySemantic proximity
Comparative efficacy of combined myo-inositol and D-chiro inositol versus metformin across PCOS Phenotypes: enhancing ovarian function, ovulation, and stress response in a prospective clinical trial.Semantic proximity
Results from the International Consensus Conference on myo-inositol and D-chiro-inositol in Obstetrics and Gynecology – assisted reproduction technologySemantic proximity
Metabolic Phenotype Predicts Biochemical Response to Inositol Supplementation in Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis.Semantic proximity
Myo-Inositol and Its Derivatives: Their Roles in the Challenges of InfertilitySemantic proximity
Melatonin and Myo-Inositol: Supporting Reproduction from the Oocyte to BirthSemantic proximity
Select a neighboring publication to make it the new centre.